Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03307395 · ClinicalTrials.gov registry record · NA
Middle Meningeal Artery Embolization for Treatment of Chronic Subdural Hematoma
A NA study of Chronic Subdural Hematoma, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- NA
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT03307395: Completed NA study of Chronic Subdural Hematoma, sponsored by Weill Medical College of Cornell University.
NCT03307395 is a NA study of Chronic Subdural Hematoma that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 6 participants, below the 1,440-participant average among 4 other Chronic Subdural Hematoma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03307395, a NA study of Chronic Subdural Hematoma, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
Middle meningeal artery (MMA) embolization via a minimally invasive endovascular approach has been attempted with the goal of eliminating the arterial supply to the vascularized membrane. The investigators have recently presented the first known case series of MMA embolization as upfront treatment for cSDH in lieu of surgical evacuation (publication pending). Five patients underwent successful embolization of the MMA with subsequent reduction in size or complete resolution of cSDH with no peri-procedural complications. The purpose of this study will be to evaluate the safety and efficacy of MMA embolization compared to traditional surgical management for symptomatic, chronic, and medically refractory SDH. MMA embolization is an established procedure used routinely for treatment of tumors or vascular malformations; this study investigates the use of an established procedure for a new disease. The investigators hypothesize that MMA embolization will afford a particularly fragile patient population an alternative to invasive and morbid neurosurgical intervention.
Primary Outcome
A neurological exam will be performed to assess any neurological changes post-procedure.
Conditions Studied
Interventions
- PROCEDURE Middel Meningeal Artery Embolization
Study Locations (1)
New York
- Weill Cornell Medical College - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-10-31 |
| Est. Completion | 2018-07-30 |
| Phase | NA |
What the finished NCT03307395 record still lists
NCT03307395 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,440-participant average among 4 other Chronic Subdural Hematoma trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Chronic Subdural Hematoma appearing as the primary indexed condition, and to 1 intervention - of which Middel Meningeal Artery Embolization is the first listed.
NCT03307395 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03307395 about?
NCT03307395 is a clinical study titled "Middle Meningeal Artery Embolization for Treatment of Chronic Subdural Hematoma". Middle meningeal artery (MMA) embolization via a minimally invasive endovascular approach has been attempted with the goal of eliminating the arterial supply to the vascularized membrane. The investigators have recently presented the first known case series of MMA embolization as upfront treatment f...
What is the current status of trial NCT03307395?
This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2017-10-31. Estimated completion is 2018-07-30.
What conditions does trial NCT03307395 study?
This clinical trial studies the following conditions: Chronic Subdural Hematoma.
What interventions are being tested in trial NCT03307395?
The interventions under investigation include: Middel Meningeal Artery Embolization (PROCEDURE).
Who is sponsoring clinical trial NCT03307395?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03307395 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Subdural Hematoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study
RECRUITING · NA
-
Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)
RECRUITING
-
Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection
RECRUITING · Phase 1
-
Microfabricated Microcatheter Advantages in Middle Meningeal Artery Embolization: an Early Experience at a Single Center
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI